{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-052110","form_type":"8-K","ticker":"RLAY","cik":"0001812364","company_name":"Relay Therapeutics, Inc.","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.279324+00:00","generated_at":"2026-06-03T00:48:48.654838+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Relay Therapeutics Q1 net loss $81.4M; cash $749.6M, Genentech milestone boosts revenue","bullets":["Net loss $81.4M ($0.62/share) vs $94.2M ($0.78/share) in Q1 2023; loss narrowed.","Revenue $10.0M vs $0.2M YoY, driven by $10M milestone from Genentech collaboration.","Cash and investments $749.6M, expected to fund operations into H2 2026.","R&D expenses $82.4M, relatively flat vs $82.8M year ago.","RLY-2608 doublet and triplet trials enrolling; lirafugratinib data and regulatory update expected H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-052110","json":"https://secwatch.observer/filing/0000950170-24-052110.json","markdown":"https://secwatch.observer/filing/0000950170-24-052110.md","text":"https://secwatch.observer/filing/0000950170-24-052110.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1812364/000095017024052110/0000950170-24-052110-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1812364/000095017024052110/rlay-20240502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T00:48:48.654838+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"63c12986b3bc761b60664c0f8fbc73cc352bdc34","claim":"Relay Therapeutics, Inc. reported first quarter 2024 results: revenue $10.0 million, net income $81.4 million, EPS $0.62.","evidence_excerpt":"The company expects its current cash, cash equivalents and investments will be sufficient to fund its current operating plan into the second half of 2026. Revenue: Revenue was $10.0 million for the first quarter of 2024, as compared to $0.2 million for the first quarter of 2023. The increase was primarily due to a payment of $10.0 million in connection with a","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1812364/000095017024052110/0000950170-24-052110-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2024"},{"label":"Revenue","value":"$10.0 million"},{"label":"Net income","value":"$81.4 million"},{"label":"EPS","value":"$0.62"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}